The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive ...
Early treatment intensification with ADT and ARPIs is now standard for mCSPC, with patient-specific factors guiding therapy selection. Enzalutamide, apalutamide, abiraterone, and darolutamide are key ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
The Revi System, an implantable tibial neuromodulation device, received FDA 510(k) clearance for its enhanced version, improving urgency urinary incontinence treatment. The OASIS trial confirmed the ...
The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...
"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...
Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...
Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback